-transparent.png){kind=logo}
m-AMSA (4'-[9'-acridinylamino]-methansulfon-m-anisidide) is an acridine derivative which has shown a wide spectrum of activity in preclinical testing. The mechanism of action is thought to be via interference with synthesis and integrity of DNA chains by intercalation between base pairs and external binding. Initial phase I clinical trials revealed granulocytopenia to be the dose limiting toxicity with occasional thrombocytopenia. Phlebitis, liver function abnormalities, and cardiac abnormalities have also been noted. Early reports suggested activity in leukemia and lymphoma. Based on these results ECOG evaluated m-AMSA in a phase II trial of Hodgkin's disease and non-Hodgkin's lymphoma.
A M Keller, and
A A Tsiatis, and
R S Neiman, and
J H Glick, and
R B Mann
March 1984,
Cancer treatment reports,
A M Keller, and
A A Tsiatis, and
R S Neiman, and
J H Glick, and
R B Mann
August 1982,
Cancer treatment reports,
A M Keller, and
A A Tsiatis, and
R S Neiman, and
J H Glick, and
R B Mann
June 1983,
European journal of cancer & clinical oncology,
A M Keller, and
A A Tsiatis, and
R S Neiman, and
J H Glick, and
R B Mann
October 1993,
Cancer,
A M Keller, and
A A Tsiatis, and
R S Neiman, and
J H Glick, and
R B Mann
November 2002,
Investigational new drugs,
A M Keller, and
A A Tsiatis, and
R S Neiman, and
J H Glick, and
R B Mann
July 1986,
Cancer treatment reports,
A M Keller, and
A A Tsiatis, and
R S Neiman, and
J H Glick, and
R B Mann
August 1984,
American journal of clinical oncology,
A M Keller, and
A A Tsiatis, and
R S Neiman, and
J H Glick, and
R B Mann
January 1993,
Investigational new drugs,
A M Keller, and
A A Tsiatis, and
R S Neiman, and
J H Glick, and
R B Mann
April 2003,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A M Keller, and
A A Tsiatis, and
R S Neiman, and
J H Glick, and
R B Mann
October 1987,
Cancer treatment reports,
